Imperial College London
Alternate

DrMatthewWilliams

Faculty of Medicine, Department of Surgery & Cancer

Honorary Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 3311 0733matthew.williams Website CV

 
 
//

Location

 

Charing Cross HospitalCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Woolf:2013:10.1016/j.clon.2013.08.002,
author = {Woolf, DK and Williams, M and Goh, CL and Henderson, DR and Menashy, RV and Simpson, N and Mastroianni, B and Collis, CH},
doi = {10.1016/j.clon.2013.08.002},
journal = {Clinical oncology (Royal College of Radiologists (Great Britain))},
pages = {734--8},
title = {Fractionated stereotactic radiotherapy for acoustic neuromas: long-term outcomes.},
url = {http://dx.doi.org/10.1016/j.clon.2013.08.002},
volume = {25},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AIMS: Acoustic neuromas are rare, benign intracranial tumours. There are a variety of treatment options, with no clear optimal management strategy and wide variation in treated outcomes. We report the outcomes from a 15 year cohort of patients treated at our centre using fractionated stereotactic radiotherapy (52.5 Gy in 25 fractions). MATERIALS AND METHODS: We analysed a retrospective case series. Patients were identified from patient records and a retrospective review of case notes and imaging reports was undertaken. We assessed tumour response using RECIST criteria and recorded toxicity. Progression-free survival was estimated using the Kaplan-Meier method. The study was conducted according to the STROBE guidelines. RESULTS: In total, 93 patients were identified; 83 patients had follow-up data, with a median follow-up period of 5.7 years. The overall control rate using RECIST criteria was 92%. Data on complications were available for 90 patients, with six (7%) experiencing a reduction in hearing, one (1%) developing trigeminal nerve dysfunction and one (1%) a deterioration in facial nerve function. Other toxicities included four (4%) patients who developed hydrocephalus, requiring the placement of a shunt and one (1%) patient who developed radiation brainstem necrosis. After further evaluation this patient was deemed to have been treated within acceptable dose constraints. CONCLUSION: These data suggest that a good control rate of acoustic neuromas is achievable using fractionated stereotactic radiotherapy to a dose of 52.5 Gy in 25 fractions. Toxicity is considered acceptable but the episode of radiation brainstem necrosis remains of concern and is the subject of further work.
AU  - Woolf,DK
AU  - Williams,M
AU  - Goh,CL
AU  - Henderson,DR
AU  - Menashy,RV
AU  - Simpson,N
AU  - Mastroianni,B
AU  - Collis,CH
DO  - 10.1016/j.clon.2013.08.002
EP  - 8
PY  - 2013///
SN  - 1433-2981
SP  - 734
TI  - Fractionated stereotactic radiotherapy for acoustic neuromas: long-term outcomes.
T2  - Clinical oncology (Royal College of Radiologists (Great Britain))
UR  - http://dx.doi.org/10.1016/j.clon.2013.08.002
UR  - http://www.ncbi.nlm.nih.gov/pubmed/23973046
VL  - 25
ER  -
Download